Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Immunology | Gastroenterology | Hepatology (Liver, Pancreatic, Gall Bladder) | Infections and Infectious Diseases
 Disease Category: Hepatitis C; Chronic
Location: United States, UT

Trial Information

Hepatitis C

A Phase I/IIa Study Assessing Single and Multiple Doses of HCV NS5A Inhibitor IDX719 in Healthy and HCV-Infected Subjects

Patient Inclusion Criteria:

  • Male or Female ages 18-65 years of age
  • BMI 18-35 kg/mg2
  • HCV treatment naïve

Patient Exclusion Criteria:

  • Co-infected with hepatitis B or HIV
  • Use or antacids or acid blockers
  • Previously received any other direct acting antiviral agents targeting the hepatitis C virus

Cher Struck, Director Marketing and Recruiting
Lifetree Clinical Research
3838 South 700 East Suite 202
Salt Lake CIty, UT 84106
Phone: 801-269-8200
Email: chers@lifetreeresearch.com

View Map

Research Center Information: Lifetree Clinical Research

If you would like to learn more about participating in this study, please send an email message using the form below.

Name:
Address:
City:
State:
Country:
Phone:
Email:  
Message:
 

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.